GSTP1-containing EVs have been shown to transmit drug resistance horizontally, suggesting their potential as negative predictors of chemoresistance and clinical outcomes in breast cancer patients receiving anthracycline/taxane treatment [108]. This evidence concerns the gene GSTP1 and breast cancer.